DEF: Beam Therapeutics Announces 2025 Annual Meeting of Stockholders

Beam Therapeutics will hold its 2025 annual meeting of stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.

Summary

• Beam Therapeutics Inc. will hold its 2025 Annual Meeting of Stockholders via live webcast on June 4, 2025, at 12:30 p.m. Eastern Daylight Time.
• The meeting will be a virtual format at www.virtualshareholdermeeting.com/BEAM2025.
• Stockholders will vote on the election of Mark Fishman, Carole Ho, and Kathleen Walsh as Class II directors for three-year terms until the 2028 annual meeting.
• They will also vote to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote will be held to approve the compensation of the named executive officers (NEOs).
• The record date for determining stockholders eligible to vote is April 8, 2025.
• Stockholders can vote over the Internet, telephone, or by mail, and are encouraged to vote by proxy.
• The proxy materials are available online at www.proxyvote.com, and a paper copy can be requested from the company.
• As of the record date, 100,557,094 shares of common stock were outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment due to the routine nature of the corporate governance activities.

Positives

• The company is providing a virtual meeting format, allowing for broader accessibility for stockholders.
• Stockholders have multiple options for voting, including online, telephone, and mail, promoting participation.
• The proxy materials are readily available online, reducing costs and environmental impact.
• The company is seeking ratification of its independent auditor, a standard practice for good corporate governance.
• The company is holding an advisory vote on executive compensation, allowing stockholders to express their views on pay practices.

Risks

• The advisory vote on executive compensation is non-binding, meaning the board is not obligated to act on the results.
• The virtual meeting format may present technical challenges for some stockholders.
• Failure to ratify the appointment of Deloitte & Touche LLP could require the audit committee to find a replacement, potentially disrupting financial reporting.

Future Outlook

The company looks forward to continued stockholder support and participation in the Annual Meeting.

Management Comments

• John Evans, Chief Executive Officer and Director, expressed gratitude for stockholders' continued support and anticipation for the Annual Meeting.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• Holding an annual meeting, soliciting proxies, and providing stockholders with voting options are standard practices for publicly traded companies in the United States.
• The virtual meeting format is increasingly common, especially among technology and biotechnology companies, to enhance accessibility and reduce costs.
• Executive compensation practices are typically benchmarked against peer companies in the same industry and of similar size, such as Allogene Therapeutics, CRISPR Therapeutics, and Editas Medicine.

Stakeholder Impact

• Shareholders have the opportunity to influence the direction of the company through their votes.
• Employees are indirectly affected by decisions regarding executive compensation and the selection of the accounting firm.
• The outcome of the director elections can impact the strategic oversight of the company.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will proceed with the Annual Meeting on June 4, 2025.
• The Board and management will consider the results of the votes and take appropriate action.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Deloitte & Touche, Voting, Virtual Meeting, Beam Therapeutics